Bristol Myers Squibb has partnered with Chai Discovery, an AI company, to use artificial intelligence for discovering therapeutic antibodies.
The collaboration will give BMS access to Chai's AI models for molecular design and folding, enabling the company to identify antibody candidates more quickly and target drug candidates that traditional methods have struggled to reach.
The partnership reflects broader adoption of AI by major pharmaceutical companies to compress drug discovery cycles.
What happened
Bristol Myers Squibb (BMS) has partnered with Chai Discovery, an AI company, to use artificial intelligence for discovering therapeutic antibodies. BMS will access Chai's AI models, including molecular folding and design capabilities, to identify antibody candidates across its drug portfolio.
Why it matters
AI is accelerating early-stage drug discovery by compressing development cycles and enabling scientists to target candidates that traditional methods have historically struggled to reach. This collaboration signals that major pharmaceutical companies are rapidly adopting AI platforms to build what BMS calls an 'AI-powered, continuously learning discovery system.' For pharmaceutical and biotech firms, the adoption of such tools may enable faster progression from concept to viable therapeutic candidates.
What to watch
BMS is the latest major pharma partner for Chai Discovery; Pfizer entered a license agreement with Chai Discovery in June to accelerate drug discovery research.
Ask the AI about this article →
Chai Discovery's partnership with Bristol Myers Squibb reflects a widening trend in the pharmaceutical industry toward integrating AI into early-stage drug development. The agreement follows Pfizer's license deal with Chai in June, indicating that large-scale biopharmaceutical companies view AI-driven molecular design as a strategic capability. Chai's platform addresses a specific pain point in drug discovery: the ability to target compounds and disease targets that conventional chemistry and screening methods have been unable to reach efficiently. By combining Chai's molecular folding and design models with BMS's deep therapeutic expertise and existing pipeline, the partnership aims to shorten the timeline from initial concept to viable therapeutic candidates—a key measure of success in early drug development where time and capital investment are substantial.
AI-summarized, only the topics you pick — one digest a day via Email, Slack, or Discord.
Free · takes 30 seconds · unsubscribe anytime
Ask AI anything about this article. Q&As are published on this page for other readers too.
Chai, an AI platform for drug discovery, announced a collaboration with Bristol Myers Squibb to use AI for ide…
Hark and AT&T have announced a partnership focused on providing connectivity solutions for future AI devices
John Deere raised its full-year 2026 profit guidance after reporting a quarterly earnings beat driven by stron…
AT&T is deploying open-source AI models to reduce its reliance on Anthropic's commercial services and lower it…
Zayo, a network infrastructure provider, has expanded its partnership with Corning, a materials science compan…
The pharmaceutical industry is increasing investment in artificial intelligence to accelerate drug discovery a…
